Form 4: OptimizeRx Corp Executive Reports Stock Transactions
SEC Form 4 Filing
Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, reports the vesting and subsequent disposal of shares to cover tax obligations.
Summary
- On October 3, 2024, Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, reported transactions involving OptimizeRx Corp [OPRX] common stock.
- 6,649 restricted stock units vested and converted into common stock.
- 1,952 shares were disposed of at $7.83 to cover tax withholding obligations.
- Following these transactions, Ms. Odence-Ford directly owns 23,195 shares of common stock and 6,649 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions, with no inherent positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common practice and required by the SEC.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they relate to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 10/03/2023 | First anniversary of the grant date of the restricted stock units, marking the beginning of the vesting period. |
| 10/03/2024 | Date of the reported transactions: vesting of restricted stock units and disposal of shares for tax obligations. |
| 10/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.